TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial

Data Show Improvement in Female Sexual Function Index with TX-004HR

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women’s healthcare
company, presented additional secondary endpoint results from the
pivotal phase 3 Rejoice Trial for its TX-004HR product candidate at the
American College of Obstetricians and Gynecologists (ACOG) Annual
Clinical and Scientific Meeting held May 14-17, 2016, in Washington, DC.

Yuvvexy™, the conditionally approved trade name for TX-004HR, is an
applicator-free vaginal estradiol softgel capsule being investigated for
the treatment of moderate-to-severe vaginal pain during sexual
intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA)
due to menopause.

Data presented in the poster assess the effect of Yuvvexy on female
sexual dysfunction in postmenopausal women using the Female Sexual
Function Index (FSFI). The FSFI is a validated, self-reporting
questionnaire consisting of 19 questions designed to assess the domains
of arousal, desire, satisfaction, orgasm, lubrication, and pain. After
12 weeks, total FSFI scores increased with all three doses of Yuvvexy (4
mcg, 10 mcg, and 25 mcg) and placebo, with a statistically significant
difference at the 10 mcg and 25 mcg doses versus placebo. The poster,
entitled “Improvement in Postmenopausal Sexual Function with TX-004HR as
Measured by FSFI,” may be viewed in the “Investors and Media” section of
the company’s website under Events and Presentations.

“We are pleased to present these additional findings from the Rejoice
Trial at ACOG as we prepare to file a New Drug Application (NDA) for
Yuvvexy as a treatment for dyspareunia, a symptom of vulvar and vaginal
atrophy due to menopause,” said TherapeuticsMD co-founder and Chief
Clinical Officer Brian Bernick, M.D. “The FSFI data reflect the breadth
and depth of our positive phase 3 Rejoice Trial and suggest that Yuvvexy
has the potential to be a highly differentiated new therapy for
menopausal women, if approved.”

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD®

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to maintain or increase
sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; the length, cost and uncertain results of
the company’s clinical trials; the potential of adverse side effects or
other safety risks that could preclude the approval of the company’s
hormone therapy drug candidates; the company’s reliance on third parties
to conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website:


TherapeuticsMD, Inc.
David Delucia, 561-961-1900
of Investor Relations
Fox, 212-257-6724
Director, Media & Engagement